



**IMMUNOHISTOCHEMICAL PROGNOSTIC PARAMETERS  
IN BREAST CARCINOMA**

**WENDY ANN RAYMOND, M.B.,B.S.**

**DIVISION OF TISSUE PATHOLOGY  
INSTITUTE OF MEDICAL AND VETERINARY SCIENCE  
ADELAIDE, SOUTH AUSTRALIA**

*awarded 3.7.90*

**THESIS SUBMITTED TO THE UNIVERSITY OF ADELAIDE  
FOR THE DEGREE OF DOCTOR OF MEDICINE**

**JANUARY 1990**

# CONTENTS

Abstract	v
Statement	vii
Contributions of this Thesis	viii
Acknowledgements	xi
CHAPTER I. INTRODUCTION	1
CHAPTER II. REVIEW OF CURRENT PROGNOSTIC INDICATORS	7
a. Tumour Size	8
b. Histological Type	10
c. Histological Grade	17
d. Vascular Invasion	23
e. Lymph Node Metastases	26
f. Hormone Receptor Status	32
g. Tumour Proliferation	43
h. Miscellaneous Factors	61
i. Conclusions	67
CHAPTER III. MATERIALS AND METHODS	70
III.1. <u>Materials</u>	71
III.2. <u>Methods</u>	76
a. Introduction	77
b. Avidin-biotin complex (ABC) staining technique	81
c. Tissues examined	84
- fresh frozen	
- paraffin-embedded	
- controls	
d. Assessment of staining	87
e. Statistical methods	91

CHAPTER IV.	<b>PROGNOSTIC PARAMETERS STUDIED</b>	92
IV.1.	<u>Lymph Node Micrometastases</u>	93
	a. Introduction	94
	b. Methodology	98
	c. Results	101
	d. Discussion	105
IV.2.	<u>Immunohistochemical Estrogen Receptor Analysis</u>	109
	a. Introduction	110
	b. Development of optimal fixation and staining procedures in imprints and frozen sections	114
	c. Frozen sections	121
	d. Imprints	124
	e. Correlation with cytosolic radioimmunoassay	129
	f. Correlation with histological and clinical parameters	131
	g. Paraffin sections	133
	- present methods	
	- fixation	
	- staining technique	
	- correlation with frozen section and cytosolic assays	
	h. Discussion	151
IV.3.	<u>Tumour Growth Fraction</u>	155
	a. Introduction	156
	b. Methodology	160
	c. Results	162
	1. Ki-67 staining	
	2. Correlation with histological grade, lymph node status and clinical parameters	166
	3. Correlation with ER content	168
	d. Discussion	170
IV.4.	<u>Intermediate Filament Protein Analysis</u>	175
	a. Introduction	176
	b. Methodology	180
	c. Results	
	1. Coexpression of cytokeratins and vimentin in benign breast epithelium	183
	2. Vimentin expression in breast carcinomas	183
	3. Correlation between vimentin expression and tumour growth fraction.	194
	d. Discussion	198

IV.5.	<u>Silver Nucleolar Organizer Regions (AgNORs)</u>	205
	a. Introduction	206
	b. Methodology	209
	c. Results	
	1. AgNOR staining of breast epithelium	
	- benign	
	- malignant	213
	2. AgNOR correlation with tumour proliferation and other clinico-pathological parameters.	218
	d. Discussion	225
IV.6.	<u>Other Traditional Protein Markers of Breast Carcinoma</u>	229
	a. Introduction	230
	b. Alpha-lactalbumin	235
	c. Pregnancy-specific $\beta_1$ -glycoprotein (SP1)	241
	d. Prolactin	246
	e. Discussion	248
IV.7.	<u>Immunohistochemical Assessment of Vascular Invasion</u>	251
	a. Introduction	252
	b. Factor VIII	254
	c. <i>Ulex europaeus</i> agglutinin I (UEA I)	259
	d. Discussion	266
IV.8.	<u>Assessment of Tumour Invasion Using Antibodies to Basement Membrane Antigens and Myoepithelial Cell Antigens</u>	268
	a. Introduction	269
	b. Type IV collagen and laminin	272
	c. Actin and muscle specific actin	285
	d. Discussion	289
CHAPTER V.	<b>CONCLUSIONS</b>	291
	a. Major prognostic parameters	292
	b. Minor prognostic parameters	294
	c. Recommendations	296

**APPENDICES**

298

- I Avidin-biotin peroxidase technique  
(paraffin sections)
- II Avidin-biotin peroxidase technique  
(frozen sections)
- III Correlation Matrix
- IV Abbreviations

299

300

301

302

**ADDENDUM**

303

**BIBLIOGRAPHY**

304

## ABSTRACT

The biological behaviour of breast cancer is unpredictable and present prognostic markers do not accurately indicate survival times for individual patients. Recent investigations have focused on a search for intracellular markers which might provide information unattainable by histology. This thesis examines the relationship between traditional pathological prognostic parameters and several new potential prognostic indicators, identified and quantified by immunohistochemical staining, in 115 malignant breast neoplasms.

A modified technique of identifying estrogen receptor (ER) protein in frozen sections and imprints utilizing a new commercial monoclonal anti-ER antibody is reported. Optimal preservation of the ER antigen is observed following fixation in periodate-lysine-paraformaldehyde (PLP) for 10 minutes. An improved, reproducible method of detecting ERs in formalin-fixed paraffin sections using the anti-ER antibody is described.

A recently synthesized monoclonal antibody to proliferating cells, Ki-67, is used to estimate the tumour growth fraction (GF) in all cases and an inverse relationship between GF and ER status is identified. Coexpression of cytokeratin and vimentin intermediate filaments (IFs) is documented, for the first time, in 10.4 per cent of ductal carcinomas. Acquisition of vimentin correlates strongly with a high tumour GF and the role of vimentin as a potential prognostic marker is discussed. Staining of nucleolar organizer regions (NORs) with the silver impregnation technique of

Crocker et al (1986) reveals a correlation between the NOR count and the Ki-67 count. Finally, it is recommended that all lymph nodes in cases of node-negative breast cancer be stained with anti-cytokeratins following the identification of "missed" micrometastases in 22 per cent of 55 cases studied by this technique.

Alpha-lactalbumin, pregnancy-specific  $\beta$ 1-glycoprotein (SP1) and prolactin, three traditional markers for breast carcinoma, are assessed and deemed non-specific and of no prognostic value. Antisera to basement membrane and myoepithelial cell antigens assist in identifying early invasive foci in intraductal carcinomas and in differentiating sclerosing adenosis from well-differentiated carcinoma. Anti-factor VIII and UEA I, employed to detect vascular invasion, provide no advantage over an assessment of haematoxylin and eosin-stained sections.

In conclusion, lymph node status and tumour GF are considered the major prognostic parameters in breast cancer. Minor prognostic markers include ER status, histological type and grade, and tumour size. Expression of vimentin IFs by breast carcinomas and NOR counts may also prove to be of prognostic value.